Recently, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as Beimei Pharm) and Jiangsu Aosaikang Pharmaceutical Co., Ltd. (hereinafter referred to as ASK Pharm) announced the strategic cooperation. Both parties will integrate the superior resources to jointly promote innovation and research and development of pediatric prescription drugs and solve unmet clinical needs in China, with a view to initiating in-depth cooperation in R&D transformation, manufacturing, sales promotion and equity cooperation.

On June 23, 2022, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharmaceutical") and Italy NTC S.r.l. (hereinafter referred to as "NTC") entered into an exclusive License and Supply Agreement for the collaboration of three EU approved Class II medical device (hereinafter referred to as "Products") in China Mainland. Beimei acquire exclusive right to register and commercialize the Products in China Mainland. The Products are oral care products, suitable for children’s use, in two different dosage forms- spray and gel as topical treatment of the oral mucosa suffering from recurrent canker sores.

Beimei Pharma’sseries B/ B+ financing roundFollowing the completion of the Series A round financing in January 2021, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharma") has recently completed the Series B and B+ financing. Led by Efung Investment Management, followed by Acer Capital, Lianrun Oriental, Hainan Jinbei and other ...

Shenzhen Beimei Pharmaceutical Co., LTD. (hereinafter referred to as "Beimei Pharmaceutical") has officially received the acceptance letter issued by the Drug Evaluation Center of the National Medical Products Administration.The sevelamercarbonate powder for oral suspension, which isimportedby Beimei Pharmaceutical,its application was accepted.In March 2022, Beimei ...

On April 1, 2022, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharmaceutical") and Netherlands Synthon B.V. (hereinafter referred to as " Synthon ") reached an exclusive license and supply agreement of a pharmaceutical product for the treatment of hyperphosphatemia (hereinafter referred to as "the product"). Under the te...

On February 24, 2022, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharmaceutical") and Dr. Reddy'slaboratory Ltd. (hereinafter referred to as "Dr. Reddy's") reached an exclusive license and supply agreement of a pharmaceutical product for the treatment of otic infection (hereinafter referred to as "the product"). ...

Shenzhen Beimei Pharmaceutical Co., Ltd. and MedPharm Ltd. (hereinafter referred to as "MedPharm") signed the Master Service Agreement (hereinafter referred to as the "Agreement") on 15th, Nov, 2021. According to the agreement, Beimei and MedPharm will cooperate in the development of a topical product for the treatment of immune diseases. MedPharm will be responsible for the preclinical research and development of products and technology transfer and will provide technical support for patent applications and product registrations. Beimei will have the exclusive right to commercialize the product in the global region, and will be responsible for the clinical study, registration, sales and promotion of the product and other commercialization activities.

Generic name:Atomoxetine Hydrochloride Oral SolutionDosage form:Oral SolutionRegistration category: Class 4The first self-developed product of Beimei, Atomoxetine Hydrochloride Oral Solution, with its dossier completion of pharmacological studies and registration data, has been filed to the Center for Drug Evaluation (CDE) of the National Medical Products Administration o...

The launch conference of Beimei Pharmaceutical’s 奥维平®Oselavir®came to a successful conclusionIn this season of harvesting joy and happiness, the launch of 奥维平® , with generic name of Oseltamivir Phosphate for Oral Suspension,was held in Shenzhen with great expectation. Experts, scholars, cooperative suppliers, agents and investors from all over the world gathered together to w...